On April 4-5, 2025, FLASCO hosted the annual FLASCO Spring Congress, featuring the Business of Oncology Summit, in Orlando, Florida. This premier gathering welcomed over 450 oncology professionals from across the state.
The theme for that year’s Business of Oncology Summit was “Leveraging AI: Shaping the Future of Oncology Business and Care.” Sessions included “AI in Oncology: From Promise to Practice,” “AI Bots,” “Using AI for Cancer Detection,” “AI in Clinical Use,” “Biopharmaceutical & AI: Bench to Bedside,” “Enhancing Care & Delivery Through AI,” and “Real‑World Experiences with AI.” Attendees also explored AI integration strategies, practice sustainability, value‑based care models, and the evolving healthcare landscape—arming them with both technical insights and business acumen to drive innovation in their own practice.
The FLASCO Spring Congress was a clinically focused event crafted for the entire cancer care team—physicians, advanced practice providers, pharmacists, nurses, and allied health professionals alike. The theme of the program was “Emerging Therapeutics and Managing the Long-Term Impact of Immunotherapy”. Attendees earned valuable continuing education (CE) hours while engaging with presentations, case‑based workshops, and interactive panel discussions. The agenda spanned a comprehensive range of clinical topics essential to modern oncology care– emerging treatment protocols and precision medicine advances to management of therapy side effects, supportive care innovations, and survivorship strategies.
Announcement
Accreditation
Photos
Posters
Posters
- Cemiplimab Monotherapy for First Line Advanced NSCLS Patients with PD-L1 Expression ≥50%: 5-Year Outcomes of EMPOWER-Lung 1
- Nivolumab subcutaneous versus nivolumab intravenous in patients with previously treated advanced or metastatic clear cell renal cell carcinoma: updated efficacy and safety results from Checkmate 67T
- Updated overall survival and safety with ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib and harboring KIT exon 11 + 17/18 mutations: ctDNA analysis from INTRIGUE
- Preliminary safety in the inavolisib + fulvestrant + ribociclib/abemaciclib arms of MORPHEUS-pan breast cancer: A Phase 1b/2 study of efficacy & safety of multiple treatment combinations in patients with metastatic/locally advanced breast cancer
- EDGE-Gastric Arm A1: Phase 2 Study of Domvanalimab (D), Zimberelimab (Z), and FOLFOX in First-line (1L) Advanced Gastroesophageal (GE) Cancer
- Effect of dose adjustments on overall survival in patients with metastatic pancreatic ductal adenocarcinoma treated with NALIRIFOX: a post hoc analysis of NAPOLI 3
- Zanidatamab in previously treated HER2-positive (HER2+) biliary tract cancer (BTC): overall survival (OS) and longer follow-up from the phase 2b HERIZON-BTC-01 study
- Optec: A Phase 2 Study to Evaluate Outpatient Step-Up Administration of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results
- Effect of Prior Selinexor Exposure on Clinical Outcomes of Chimeric Antigen Receptor T-cell (CAR-T) Therapy for Relapsed/Refractory Multiple Myeloma (RRMM): A Real-World Descriptive Analysis
- MagnetisMM-3: long-term update and outcomes of less frequent dosing of elranatamab (ELRA) in relapsed/refractory multiple myeloma
- Tagraxofusp plus venetoclax and azacitidine in patients ineligible for intensive chemotherapy with previously untreated CD123+ acute myeloid leukemia: a phase 2 multicenter trial
- Belantamab mafodotin, bortezomib, and dexamethasone vs daratumumab, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma: Overall survival analysis and updated efficacy outcomes of the phase 3 DREAMM-7 trial
Presentations
Business of Oncology Summit Presentations
- “AI in Oncology: From Promise to Practice” by Christopher Merlan
- “AI in Clinical Use” by Dean Dalili, MD, MHCM
FLASCO Spring Congress Presentations
- “Immune Checkpoint Inhibitors – Navigating Difficult Toxicities” by Nayef Abdel-Razeq, MD
- “Immune Checkpoint Inhibitors – Managing Difficult Toxicities” by Jeanelle King, PA-C
- “Cardiovascular Management of Patients Treated With Immune Checkpoint Inhibitors” by Diego Sadler, MD, FACC
- “Neurotoxicity of Immune Checkpoint Inhibitors” by Fernando Santos Pinheiro, MD
- “Management of HER2 Low Metastatic Breast Cancer- Case 1” by Tanmayi Pai, MD
- “Management of HER2 Low Metastatic Breast Cancer- Case 2” by Turab Mohammed, MD
- “Management of HER2 Low Metastatic Breast Cancer- Case 3” by Samantha El Warrak, MD
- “Hodgkins Lymphoma Update” by Daniel Alan Kerr II, MD, PhD
- “Updates in Therapies for Refractory Thyroid Cancer” by Cesar Perez Batista, MD
- “WHO Classification of Thyroid Cancer” by William Westra, MD
